Thanks, though Graham seems to agree with my proposition:
"The VISION study compared Lu-PSMA-617 with standard of care in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received at least two previous lines of therapy ...This compares with the LuPIN trial that tested the combination of Lu-PSMA-617 and Veyonda in men with end-stage mCRPC who had progressed on at least three previous lines of therapy."
(from today's announcement; my emphasis)
Thanks, though Graham seems to agree with my proposition:"The...
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
0.014(14.6%) |
Mkt cap ! $28.34M | |||
| Open | High | Low | Value | Volume |
| 9.2¢ | 11.5¢ | 9.2¢ | $53.30K | 518.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 48681 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 74195 | 4 |
View Market Depth
| Last trade - 15.45pm 23/08/2024 (20 minute delay) ? |
| NOX (ASX) Chart |